SCHEMBL3363073

SCHEMBL3363073

CN1CCCN(C(=O)c2cccc(-c3ccc(C=C4C(=O)NC(=O)N4C)o3)c2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 10/20 0.67
PIM2 Q9P1W9 8/20 0.67
FLT3 P36888 2/20 0.67
PIM3 Q86V86 1/20 0.67
PIK3CG P48736 3/20 0.45
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.42
GFER P55789 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
PDE5A O76074 1/20 0.41
PDE1A P54750 1/20 0.41
PDE1B Q01064 1/20 0.41
PDE4D Q08499 1/20 0.41
PDE7A Q13946 1/20 0.41
PDE1C Q14123 1/20 0.41
PDE3A Q14432 1/20 0.41
TLR9 Q9NR96 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3363065 1.00 PIM1 (0.67) PIM1PIM2FLT3PIM3PIK3CG
SCHEMBL12990510 1.00 PIM1 (0.67) PIM1PIM2FLT3PIM3PIK3CG
SCHEMBL3425697 0.89 PIM1 (0.53) PIM1PIM2FLT3PIM3GSK3A
SCHEMBL3425692 0.89 PIM1 (0.53) PIM1PIM2FLT3PIM3GSK3A
SCHEMBL12990207 0.89 PIM1 (0.53) PIM1PIM2FLT3PIM3GSK3A
SCHEMBL3363068 0.88 PIM1 (0.64) PIM1PIM2FLT3PIM3PIK3CG
SCHEMBL12990513 0.86 PIM1 (0.67) PIM1PIM2FLT3PIM3PIK3CG
SCHEMBL3363071 0.86 PIM1 (0.67) PIM1PIM2FLT3PIM3PIK3CG
SCHEMBL3363075 0.86 PIM1 (0.67) PIM1PIM2FLT3PIM3PIK3CG
SCHEMBL3363324 0.85 PIM1 (0.66) PIM1PIM2FLT3PIM3PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PIM1 2/4885PIM2 1/4885FLT3 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.